Compare Cipla with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs LUPIN - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA LUPIN CIPLA/
LUPIN
 
P/E (TTM) x 29.8 -18.7 - View Chart
P/BV x 4.2 2.1 201.5% View Chart
Dividend Yield % 0.5 1.0 50.5%  

Financials

 CIPLA   LUPIN
EQUITY SHARE DATA
    CIPLA
Mar-21
LUPIN
Mar-21
CIPLA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs8791,122 78.3%   
Low Rs411576 71.3%   
Sales per share (Unadj.) Rs237.6334.2 71.1%  
Earnings per share (Unadj.) Rs29.827.0 110.1%  
Cash flow per share (Unadj.) Rs43.046.6 92.3%  
Dividends per share (Unadj.) Rs5.006.50 76.9%  
Avg Dividend yield %0.80.8 101.3%  
Book value per share (Unadj.) Rs226.7300.1 75.6%  
Shares outstanding (eoy) m806.46453.68 177.8%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.72.5 106.8%   
Avg P/E ratio x21.631.4 69.0%  
P/CF ratio (eoy) x15.018.2 82.3%  
Price / Book Value ratio x2.82.8 100.5%  
Dividend payout %16.824.0 69.8%   
Avg Mkt Cap Rs m519,826385,072 135.0%   
No. of employees `000NANA-   
Total wages/salary Rs m32,51828,259 115.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m191,596151,630 126.4%  
Other income Rs m2,6981,363 197.9%   
Total revenues Rs m194,294152,993 127.0%   
Gross profit Rs m42,48725,669 165.5%  
Depreciation Rs m10,6778,874 120.3%   
Interest Rs m1,6071,406 114.3%   
Profit before tax Rs m32,90116,751 196.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,8884,485 198.2%   
Profit after tax Rs m24,01312,266 195.8%  
Gross profit margin %22.216.9 131.0%  
Effective tax rate %27.026.8 100.9%   
Net profit margin %12.58.1 154.9%  
BALANCE SHEET DATA
Current assets Rs m132,095139,864 94.4%   
Current liabilities Rs m45,91684,361 54.4%   
Net working cap to sales %45.036.6 122.9%  
Current ratio x2.91.7 173.5%  
Inventory Days Days6869 97.8%  
Debtors Days Days7108 6.1%  
Net fixed assets Rs m116,27794,439 123.1%   
Share capital Rs m1,613907 177.7%   
"Free" reserves Rs m181,232135,229 134.0%   
Net worth Rs m182,844136,136 134.3%   
Long term debt Rs m12,028161 7,461.2%   
Total assets Rs m248,372234,302 106.0%  
Interest coverage x21.512.9 166.3%   
Debt to equity ratio x0.10 5,555.2%  
Sales to assets ratio x0.80.6 119.2%   
Return on assets %10.35.8 176.8%  
Return on equity %13.19.0 145.8%  
Return on capital %17.713.3 132.9%  
Exports to sales %31.30-   
Imports to sales %10.90-   
Exports (fob) Rs m59,951NA-   
Imports (cif) Rs m20,911NA-   
Fx inflow Rs m68,05151,027 133.4%   
Fx outflow Rs m20,91121,081 99.2%   
Net fx Rs m47,14029,946 157.4%   
CASH FLOW
From Operations Rs m37,55218,218 206.1%  
From Investments Rs m-23,872-12,396 192.6%  
From Financial Activity Rs m-13,299-18,853 70.5%  
Net Cashflow Rs m509-13,031 -3.9%  

Share Holding

Indian Promoters % 13.5 46.5 29.0%  
Foreign collaborators % 20.1 0.3 7,192.9%  
Indian inst/Mut Fund % 48.6 41.9 116.2%  
FIIs % 26.6 14.7 181.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 53.2 124.7%  
Shareholders   418,584 378,547 110.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUN PHARMA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    PIRAMAL ENTERPRISES    



Today's Market

Sensex Ends 150 Points Lower, Nifty Falls Below 15,800; FMCG & Banking Stocks Witness Selling(Closing)

After opening deep in the red, Indian share markets recovered most of the losses as the session progressed but still ended on a negative note.

Related Views on News

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

The Greatest Dividend Stock of All Time is...(Views On News)

Jun 16, 2022

Prudent investors should consider dividend aristocrats to create passive, predictable, and growing income to rely on whether the market moves up or down in these uncertain times.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jun 29, 2022 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS